Fibrocell Science to Present at Jefferies 2014 Global Healthcare Conference
Jefferies 2014 Global Healthcare Conference
EXTON, Pa. -- May 29, 2014
Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company
primarily focused on developing first-in-class treatments for rare and serious
skin and connective tissue diseases with high unmet medical needs, today
announced that David Pernock, chairman and chief executive officer, and Greg
Weaver, senior vice president and chief financial officer, ofFibrocell
Science will present at the Jefferies 2014 Global Healthcare Conference at 3
p.m. EDT on Thursday, June 5, 2014, in New York City. Mr. Pernock and Mr.
Weaver will discuss the company’s autologous fibroblast technology, its
therapeutic candidates in development, and its collaboration with Intrexon
Corporation (NYSE:XON) to develop genetically-modified personalized biologics.
A live webcast of the presentation will be available on Fibrocell's website at
presentation will be archived on the company's website and available for 90
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (NYSE MKT:FCSC) is an autologous cell therapy company
primarily focused on developing first-in-class treatments for skin diseases
and conditions with high unmet medical needs. Based on its proprietary
autologous fibroblast technology, Fibrocell is pursuing breakthrough medical
applications of azficel-T for restrictive burn scarring and vocal cord
scarring. The company’s collaboration with Intrexon Corporation (NYSE:XON), a
leader in synthetic biology, includes using genetically-modified fibroblasts
for treating orphan skin diseases for which there are no currently approved
products. For additional information, visit www.fibrocellscience.com.
Fibrocell Science, Inc.
Gregory Weaver, +1 484-713-6000
Senior Vice President and Chief Financial Officer
S.A. Noonan Communications, LLC
Susan Noonan, 212-966-3650
Press spacebar to pause and continue. Press esc to stop.